Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer

Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients... Esophageal cancer patients frequently succumb to their disease. However, patients treated with neoadjuvant therapy who achieve pCR have a higher rate of R0 resections, fewer recurrences, and improved 5-year OS and DFS. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Surgical Oncology Springer Journals

Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer

Loading next page...
 
/lp/springer-journals/pathologic-response-after-neoadjuvant-therapy-is-the-major-determinant-3qfzyHFy0b

References (42)

Publisher
Springer Journals
Copyright
Copyright © 2010 by Society of Surgical Oncology
Subject
Medicine & Public Health; Surgery ; Oncology ; Surgical Oncology
ISSN
1068-9265
eISSN
1534-4681
DOI
10.1245/s10434-009-0862-1
pmid
20140529
Publisher site
See Article on Publisher Site

Abstract

Esophageal cancer patients frequently succumb to their disease. However, patients treated with neoadjuvant therapy who achieve pCR have a higher rate of R0 resections, fewer recurrences, and improved 5-year OS and DFS.

Journal

Annals of Surgical OncologySpringer Journals

Published: Feb 6, 2010

There are no references for this article.